serine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Nagatsu, T | 1 |
| Narabayashi, H | 1 |
| Karunakaran, S; Ravindranath, V | 1 |
| Greene, LA; Jackson-Lewis, V; Jin, ZH; Malagelada, C; Przedborski, S | 1 |
| Bao, XQ; Cao, SN; Hu, JP; Li, Y; Wang, XL; Wang, YD; Xu, S; Yu, SS; Yu, WW; Zhang, D | 1 |
| Bassareo, V; Bezard, E; Calabresi, P; Capasso, M; Carta, M; Di Maio, A; Errico, F; Li, Q; Morelli, M; Nuzzo, T; Parekh, P; Serra, M; Servillo, F; Sulzer, D; Thiolat, ML; Usiello, A | 1 |
1 review(s) available for serine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
[Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Dopamine Agents; Droxidopa; Humans; Levodopa; Nerve Tissue; Parkinson Disease; Pyridines; Serine | 1988 |
5 other study(ies) available for serine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques | 1986 |
Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; bcl-Associated Death Protein; Cell Nucleus; Dopamine Agents; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Imidazoles; Male; Mice; Mice, Inbred C57BL; Neurons; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Protein Transport; Pyrimidines; Serine; Substantia Nigra; Time Factors | 2009 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; PC12 Cells; Protein Serine-Threonine Kinases; Rats; Serine; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transcription Factors; Transfection; Tyrosine 3-Monooxygenase | 2010 |
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Discovery; Male; Mice, Inbred ICR; Mice, Transgenic; Neuroprotective Agents; Parkinson Disease, Secondary; Phloroglucinol; Serine; Signal Transduction; src-Family Kinases | 2016 |
Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Corpus Striatum; Dopamine; Homeostasis; Mesencephalon; Mice; Putamen; Serine | 2023 |